Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial - 11/08/17
Dafna Gladman, MD, University of Toronto; William Rigby, MD, Dartmouth Hitchcock Medical Center; Valderilio Azevedo, MD, Federal University of Parana; Frank Behrens, MD, Johann Wolfgang Goethe University; Ricardo Blanco, PhD, Hospital Universitario Marques; Andrzej Kaszuba, MD, Specialstyczne Gabinety Lerkarskie “DERMED”; Cunshan Wang, PhD, Pfizer Inc; Sujatha Menon, PhD, Pfizer Inc; Thijs Hendrikx, PhD, Pfizer Inc
Le texte complet de cet article est disponible en PDF. Commercial support: This study was sponsored by Pfizer Inc. Medical writing support was provided under direction from the authors by Amanda Pedder of Complete Medical Communications and funded by Pfizer Inc. |
Vol 76 - N° 6S1
P. AB114 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?